A BUDGET IMPACT ANALYSIS TO ESTIMATE THE ECONOMIC IMPACT OF DRUG ELUTING BALLOON FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASE

Author(s)

Corbo M*1;Beccagutti G1, Manda B2 1Medtronic Italia, Sesto San Giovanni, Italy, 2Medtronic Vascular Inc., Santa Rosa, CA, USA

OBJECTIVES: Drug Eluting Balloon (DEB) is a promising alternative for the treatment of patients with peripheral arterial disease, due to the potential reduction in re-intervention rates and cost-savings compared to other technologies commonly used. The objective of this analysis was to assess the economic impact of DEB and other endovascular therapies for patients with femoral-popliteal disease. METHODS: A budget impact model was developed to compare the relative impact in Italy of four different index procedure treatments (PTA with regular balloons, DEB, bare metal stents (BMS) and drug eluting stents (DES)) based on the repeat procedure rates (TLR - target lesion revascularization) over 1 year. The model was developed from a Italian national healthcare system (NHS) perspective with a 5-year time horizon. A systematic literature review was carried out on TLR rates in patients with femoral-popliteal disease treated with one of the four treatment choices. Costs associated to each treatment are derived from the average DRG tariffs used for peripheral angioplasty procedures. A decision analytic model was developed to estimate total costs over 12 months of index procedures and possible revascularizations. RESULTS: Pooled 12-month TLR rates show clear patients benefit with DEB compared to PTA (8,6% vs 28,6%) and non-inferiority of DEB vs DES (9,4%) and BMS (11,5%). Total Italian DRG payments for index and repeat interventions (based on TLR rates estimation) across treatments showed that DEB was the least costly treatment strategy over 1 year, with saving of almost €1,000 per patient with DEB vs PTA. Based on these per-patient savings, the potential total savings amounted to approximately €2 million for an assumed annual increase of 5% in DEB adoption rate over 5 years. CONCLUSIONS: The analysis suggests clear patient benefit for DEB. Despite initial higher investments, DEB represents a cost-saving alternative to other technologies according to the NHS perspective.

Conference/Value in Health Info

2013-11, ISPOR Europe 2013, The Convention Centre Dublin

Value in Health, Vol. 16, No. 7 (November 2013)

Code

PCV40

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×